Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

616 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH; mRNA-1273 Study Group. Widge AT, et al. Among authors: mascola jr. N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3. N Engl J Med. 2021. PMID: 33270381 Free PMC article. No abstract available.
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL. Mascola JR, et al. J Virol. 2005 Jan;79(2):771-9. doi: 10.1128/JVI.79.2.771-779.2005. J Virol. 2005. PMID: 15613305 Free PMC article.
HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity.
Louder MK, Sambor A, Chertova E, Hunte T, Barrett S, Ojong F, Sanders-Buell E, Zolla-Pazner S, McCutchan FE, Roser JD, Gabuzda D, Lifson JD, Mascola JR. Louder MK, et al. Among authors: mascola jr. Virology. 2005 Sep 1;339(2):226-38. doi: 10.1016/j.virol.2005.06.003. Virology. 2005. PMID: 16005039 Free article.
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JG, King CR, Andrews CA, Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS; Vaccine Research Center 006 Study Team. Catanzaro AT, et al. Among authors: mascola jr. J Infect Dis. 2006 Dec 15;194(12):1638-49. doi: 10.1086/509258. Epub 2006 Nov 8. J Infect Dis. 2006. PMID: 17109335 Free PMC article. Clinical Trial.
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ; Vaccine Research Center 004 Study Team. Graham BS, et al. Among authors: mascola jr. J Infect Dis. 2006 Dec 15;194(12):1650-60. doi: 10.1086/509259. Epub 2006 Nov 8. J Infect Dis. 2006. PMID: 17109336 Free PMC article. Clinical Trial.
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.
Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, Graham BS; VRC 007 Study Team. Catanzaro AT, et al. Among authors: mascola jr. Vaccine. 2007 May 16;25(20):4085-92. doi: 10.1016/j.vaccine.2007.02.050. Epub 2007 Mar 7. Vaccine. 2007. PMID: 17391815 Clinical Trial.
616 results